Evidence map›Paper›PMID 39050548›Full record

ArticleHemaSphere2024

The role of trephine bone marrow biopsies in the era of measurable residual disease

Nadine Kutsch, Sandra Robrecht, Anna Fink, Elisabeth Lange, Rudolf Weide, Michael G Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling-Kaiser, Georg Köchling and 16 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00769522 (Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00769522 phase3completednot on this map

Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia

TypeinterventionalSponsorGerman CLL Study GroupRan2008 to 2018Enrolled564ConditionsChronic Lymphocytic LeukemiaArmsRituximab, Bendamustine, Cyclophosphamide, Fludarabine
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Nadine KutschDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group University of Cologne Cologne Germany.ORCID 0000-0001-9559-8575
Sandra RobrechtDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group University of Cologne Cologne Germany.
Anna FinkDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group University of Cologne Cologne Germany.
Elisabeth LangeDepartment of Hematology and Oncology Evangelical Hospital Hamm Hamm Germany.
Rudolf WeidePractice for Hematology and Oncology Koblenz Germany.
Michael G KiehlDepartment of Internal Medicine Frankfurt (Oder) General Hospital Frankfurt/Oder Germany.
Martin SöklerDepartment II of Internal Medicine University Hospital Tübingen Tübingen Germany.
Rudolf SchlagPractice for Oncology Würzburg Germany.
Ursula Vehling-KaiserOncology and Palliative Care, Dayclinic Landshut Landshut Germany.
Georg KöchlingPrivate Oncology Practice Villingen-Schwenningen Germany.
Christoph PlögerPrivate Oncology Practice Mannheim Germany.
Michael GregorDivision of Hematology Cantonal Hospital of Lucerne Lucerne Switzerland.
Torben PlesnerDepartment of Hematology and University of Southern Denmark Vejle Hospital Vejle Denmark.
Michael R ClausenDepartment of Hematology and University of Southern Denmark Vejle Hospital Vejle Denmark.
Ilske OschliesHematopathology Section Christian-Albrechts-University Kiel Kiel Germany.
Matthias RitgenDepartment II of Internal Medicine University of Schleswig-Holstein Kiel Germany.
Marco HerlingDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group University of Cologne Cologne Germany.
Kirsten FischerDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group University of Cologne Cologne Germany.
Hartmut DöhnerDepartment III of Internal Medicine University Hospital of Ulm Ulm Germany.
Clemens-Martin WendtnerDepartment III of Internal Medicine University Hospital, LMU Munich Germany.
Karl-Anton KreuzerDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group University of Cologne Cologne Germany.
Stephan StilgenbauerDepartment of Hematology and Oncology Hospital STS AG Thun Thun Switzerland.
Michael HallekDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group University of Cologne Cologne Germany.
Sebastian BöttcherDepartment III of Internal Medicine Medicine-Hematology/Oncology/Palliative Care Rostock University Medical Center Rostock Germany.
Wolfram KlapperHematopathology Section Christian-Albrechts-University Kiel Kiel Germany.ORCID 0000-0001-7208-4117
Barbara EichhorstDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group University of Cologne Cologne Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39050548
PMCPMC11267170

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.